Abstract
Most anticancer agents act by inducing apoptosis in sensitive tumor cells. Hence, in many types of cancers, significant increase of tumor apoptosis after chemotherapy correlates with tumor chemosensitivity. Theoretically, a reliable evaluation of apoptotic changes, postchemotherapy to baseline, may provide valuable insights into the apoptotic competence of cancers. Until now, assessment of chemosensitivity has usually relied upon histological evidence of tumor response (i.e., partial or complete disappearance of tumor cells) or demonstration of tumor shrinkage by means of morphological imaging (i.e., computed tomography or magnetic resonance imaging). In clinical practice, however, these conventional methods are proving ineffective for monitoring tumor chemosensitivity on a daily basis. Recent developments in molecular imaging have allowed the synthesis of a new radiolabeled agent, 99mTc-recombinant human Annexin A5, designed to the assessment of apoptotic response of cancers after a single course of chemotherapy. Such in vivo technique opens promising perspectives for evaluating, noninvasively and early, tumor response to anticancer therapies. Alternative methods for Annexin A5 labeling and imaging may improve the detection of drug-induced apoptosis to monitor chemosensitivity.
Key Words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Staunton, M. J. and Gaffney, E. F. (1995) Tumor type is a determinant of suscep tibility to apoptosis. Am. J. Clin. Pathol. 103, 300–307.
Symmans, W. R, Volm, M. D., Shapiro, R. L., et al. (2000) Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatments. Clin. Cancer Res. 6, 4610–4617.
Ghosh, M., Crocker, J., and Morris, A. (2001) Apoptosis in squamous cell carci noma of the lung: correlation with survival and clinicopathological features. J. Clin. Pathol. 54, 111–115.
Fox, E., Curt, G. A., and Balis, F. M. (2002) Clinical trial design for target-based therapy. Oncologist 7, 401–407.
Dive, C., Evans, C. A., and Whetton, A. D. (1992) Induction of apoptosis-new targets for cancer chemotherapy. Semin. Cancer Biol. 3, 417–427.
Workman, P. (2002) Challenges of PK/PD measurements in modern drug devel opment. Eur. J. Cancer 38, 2189–2193.
Workman, P. and Kaye, S. B. (2002) Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 4(Suppl.), S1–S9.
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., et al. (2000) New guidelines to evaluate response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205–216.
Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. (1994) Apoptosis-its signif icance in cancer and cancer therapy. Cancer 73, 2013–2026.
Hickman, J. A. (1992) Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 11, 121–139.
Kaufmann S. H. and Earnshaw W. C. (2000) Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256, 42–49.
Mow, B. M. E, Blajeski, A. L., Chandra, J., and Kaufman, S. H. (2001) Apopto sis and the response to anticancer therapy. Curr. Opin. Oncol. 13, 453–462.
Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., et al. (1995) Early redistri bution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by over expression of Bcl-2 and Abl. J. Exp. Med. 182, 1545–1556.
Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., and Henson, P. M. (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207–2216.
Huber, R., Berendes, R., Burger, A., et al. (1992) Crystal and molecular structure of human annexin V after refinement. Implications for structure, membrane bind ing and ion channel formation of the annexin family of proteins. J. Mol. Biol. 223, 683–704.
Reutelingsperger, C. P. M. (2001) Annexins: key regulators of haemostasis, thrombosis, and apoptosis. Thromb. Haemost. 86, 413–419.
Mesner, P. W. and Kaufmann, S. H. (1997) Methods utilized in the study of apoptosis. Adv. Pharmacol. 41, 57–87.
Blankenberg, F. G., Katsikis, P. D., Tait, J. R, et al. (1998) In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. USA 95, 6349–6354.
Blankenberg, F. G., Katsikis, P. D., Tait, J. F., et al. (1999) Imaging of apoptosis (programmed cell death) with 99mTc Annexin V. J. Nucl. Med. 40, 184–191.
Ohtsuki, K., Akashi, K., Aoka, Y., et al. (1999) Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur. J. Nuclear Med. 26, 1251–1258.
Vriens, P. W., Blankenberg, F. G., Stoot, J. H., et al. (1998) The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejec tion. J. Thorac. Cardiovasc. Surg. 116, 844–853.
Ogura, Y., Krams, S. M., Martinez, O. M., et al. (2000) Radiolabeled Annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology 214, 795–800.
Blankenberg, F. G., Robbins, R. C., Stoot, J. H., et al. (2000) Radionucleide imag ing of acute lung transplant rejection with annexin V. Chest, 117, 834–840.
D’Arceuil, H., Rhine, W., de Crespigny, A., et al. (2000) 99mTc annexin V imaging of neonatal hypoxic brain injury. Stroke 31, 2692–2700.
Blankenberg, F. G., Naumovski, L., Tait, J. F., Post, A. M., and Strauss, H. W. (2001) Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. J. Nucl. Med. 42, 309–316.
Hofstra, L., Liem, I. H., Dumont, E. A., et al. (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356, 209–212.
Narula, J., Acio, E. R., Narula, N., et al. (2001) Annexin-V imaging for noninva sive detection of cardiac allograft rejection. Nat. Med. 7, 1347–1352.
Kown, M. H., Strauss, H. W., Blankenberg, F. G., et al. (2001) In vivo imaging of acute cardiac rejection in human patients using 99mtechnetium labeled Annexin V. Am. J. Transpl. 1, 270–277.
Hofstra, L., Thimister, P. W. L., DeBruine, A. P., et al. (2001) In vivo detection of apoptosis in an intracardiac tumor. JAMA 14, 1841.
Mochizuki, T., Kuge, Y., Zhao, S., et al. (2003) Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-Annexin V. J. Nuclear Med. 44, 92–97.
Belhocine, T. Z., Steinmetz, N., Hustinx, R., et al. (2002) Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8, 2766–2774
Kasina, S., Rao, T. N., Srinivasan, A., et al. (1991) Development and biologic eval uation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J. Nuclear Med. 32, 1445–1450.
Green, A. M. and Steinmetz, M. D. (2002) Monitoring apoptosis in real time. Cancer J. 8, 82–92.
Kemerink, G. J., Boersma, H. H., Thimister, P. W. L., et al. (2001) Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans. Eur. J. Nuclear Med. 28, 1373–1378.
Kemerink, G. J., Liu, X., Kieffer, D., et al. (2003) Safety, biodistribution, and dosimetry of 99mTc-HYNIC-Annexin V, a novel human recombinant Annexin V for human application. J. Nuclear Med. 44, 947–952.
Subbarayan, M., Häfeli, U. O., Feyes, D. K., Unnithan, J., Emancipator, S. N., and Mukhtar, H. (2003) A simplified method for preparation of 99mTc-Annexin V and its biologic evaluation for in vivo imaging of apoptosis after photodynamic therapy. J. Nuclear Med. 44, 650–656.
Blankenberg, F. G., Tait, J., and Strauss, H. W. (2000) Apoptotic cell death: its implications for imaging in the next millennium. Eur. J. Nuclear Med. 27, 359–367.
Yang, D. J., Azhdarinia, A., Wu, P., et al. (2001) In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-Annexin V. Cancer Biother. Radiopharm. 16, 73–83.
Tait, J. E, Brown, D. S., Gibson, D. E, Blankenberg, EG., and Strauss, H. W. (2000) Development and characterization of Annexin V mutants with endogenous chelation sites for 99mTc. Bioconjugate Chem. 11, 918–925.
Ke, S., Wen, X., Wu, Q.-P., et al. (2004) Imaging taxane-induced tumor apoptotic using PEGylated, 111in-labeled Annexin V. J. Nuclear Med. 45, 108–115.
Lahorte, C, Siegers, G., Philippe, J., Van de Wiele, C., and Dierckx, R. A. (2001) Synthesis and in vitro evaluation of 123I-labelled human recombinant Annexin V. Bio. Eng. 17, 51–53.
Ito, M., Tomiyoshi, K., Takahashi, N., et al. (2002) Development of a new ligand, 11C-labeled Annexin V, for PET imaging of apoptosis. Proc. SNM 49th Annual Meeting, No. 1457.
Russell, J., O’Donoghue, J. A., Finn, R., Finn, R., et al. (2002) Iodination of Annexin V for imaging apoptosis. J. Nuclear Med. 43, 671–677.
Glaser, M., Collingridge, D. R., Aboagye, E., et al. (2003) Iodine-124 labelled Annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl. Radiat. Isot. 58, 55–62.
Dekker, B., Keen, H., Zweit, J., et al. (2002) Detection of cell death using 124I-Annexin V. Proc. SNM 49th Annual Meeting, No. 256.
Keen, H., Dekker, B., Disley, L., et al. (2003) Iodine-124 labelled Annexin V for PET imaging of in vivo cell death. Proc. SNM 50th Annual Meeting, No. 586.
Smith-Jones, P. M., Afroze, A., Zanzonico, P., Tait, J., Larson, S. M., and Strauss, H. W. (2003) 68Ga labelling of Annexin-V: comparison to 99mTc-Annexin-V and 67Ga-Annexin. Proc. SNM 50th Annual Meeting, No. 159.
Zijlstra, S., Gunawan, J., and Burchert, W. (2003) Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantifica tion of apoptotic cells with PET. Appl. Radiat. Isot. 58, 201–207.
Vaidayanathan, G. and Zalutsky, M. R. (1992) Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F] fluorobenzoate. Int. J. Rad. Appl. Instrum. B 19, 275–281.
Boisgard, R., Blondel, A., Dolle, F., et al. (2003) A new 18F tracer for apoptosis imaging in tumor bearing mice. Proc. SNM 50th Annual Meeting, No. 157.
Mease, R. C., Weinberg, I. N., Toretsky, J. A., and Tait, J. F. (2003) Preparation of F-18 labeled Annexin V: a potential PET radiopharmaceutical for imaging cell death. Proc. SNM 50th Annual Meeting, No. 1058.
Beyer, T., Townsend, D. W., Brun, T., et al. (2000) A combined PET/CT scanner for clinical oncology. J. Nuclear Med. 41, 1369–1379.
Townsend, D. W. and Beyer, T. (2002) A Combined PET/CT scanner: the path to true image fusion. Br. J. Radiol. 75(Suppl.), S24–30.
Steinert, H. C. and von Schulthess, G. K. (2002) Initial clinical experience using a new integrated in-line PET/CT system. Br. J. Radiol. 75(Suppl.), S36–S38.
Takei, T., Kuge, Y., Zhao, S., et al. (2003) The time course of apoptotic tumor response following a single dose of chemotherapy: evaluation with 99mTc-Annexin V, caspase-3, expression and TUNEL staining in an experimental tumor model. Proc. SNM 50th Annual Meeting, No. 583.
Blankenberg, F. (2002) To scan or not scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin. Cancer Res. 8, 2757–2758.
Geske, F. J., Monks, J., Lehman, L., and Fadok, V. A. (2002) The role of the macrophages in apoptosis: hunter, gatherer, and regulator. Int. J. Hematol. 76, 16–26.
Geske, F. J., Monks, J., Lehman, L., and Fadok, V. A. (2001) Early stages of p53 induced apoptosis are reversible. Cell Death Differ. 8, 182–191.
Hammill, A. K., Urh, J. W., and Scheuermann, R. H. (1999) Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell Res. 251, 16–21.
Martin, S., Pombo, I., Poncet, P., David, B., Arock, M., and Blank, U. (2000) Immunologic stimulation of mast cells leads to reversible exposure of phos phatidylserine in the absence of apoptosis. Int. Arch. Allergy Immunol. 123, 249–258.
Allman, R., Errington, R. J., and Smith, P. J. (2003) Delayed expression of apop tosis in human lymphoma cells undergoing low-dose Taxol-induced mitotic stress. Br. J. Cancer 88, 1649–1658.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Belhocine, T.Z., Blankenberg, F.G. (2005). 99mTc-Annexin A5 Uptake and Imaging to Monitor Chemosensitivity. In: Blumenthal, R.D. (eds) Chemosensitivity: Volume II. Methods in Molecular Medicine™, vol 111. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-889-7:363
Download citation
DOI: https://doi.org/10.1385/1-59259-889-7:363
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-58829-586-6
Online ISBN: 978-1-59259-889-2
eBook Packages: Springer Protocols